Navigation Links
Absorption Pharmaceuticals' CEO Jeff Abraham Discusses Promescent on KFI
Date:8/8/2014

LOS ANGELES, Aug. 8, 2014 /PRNewswire/ -- Jeff Abraham, CEO for Absorption Pharmaceuticals, was featured on KFI AM 640 on Wednesday, August 6, 2014, where he discussed Promescent, the first FDA-approved treatment for premature ejaculation (PE). Abraham answered callers' question regarding PE and explained how Promescent would safely and effectively improve their sex lives. 

According to statistics, more than 30 percent of men are currently struggling with premature ejaculation, much larger than the number of men who suffer from erectile dysfunction, a $10B worldwide market.  In his segment on KFI, Jeff Abraham explained how Promescent is able to provide men with superior ejaculatory control, with an extremely low side effect profile, common concerns surrounding other treatments for the disorder.

"Promescent may seem like a miracle, but it is actually just great science," says Abraham.  "Using a precise ratio of active ingredients, Promescent is able to absorb through the skin's outermost layer to the nerves below that control ejaculation.  This means men are not deprived of sensation and neither are their partners."

Listen to the full KFI interview with Absorption Pharmaceuticals CEO Jeff Abraham here:

http://www.kfiam640.com/media/podcast-john-and-ken-on-demand-JohnandKen/jane-wells-cnbc-6pm-86-25128155/

Promescent is now considered the leading PE solution in the U.S. with solid support from the medical community. Leaders in sexual medicine along with more than 1,000 urologists use Promescent as first-line therapy for premature ejaculation, replacing off-label anti-depressants and EMLA topical anesthetic.

"We're finding that an increasing portion of our business is from men who don't suffer from PE but simply want to last longer in bed," says Abraham.  "This helps men better satisfy their partners and gain sexual confidence."

Promescent is available on-line and over-the-counter at independent pharmacies across the nation.  It is safe, effective, and doctor recommended. 

For more information, please visit http://www.promescent.com/.

To set up an interview and/or media inquiries, call Tyler Barnett at 323.937.1951.


'/>"/>
SOURCE Absorption Pharmaceuticals
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Absorption Systems announces novel test platform for interactions with the BCRP transporter
2. Absorption Systems Registers with FDA as a Generic Drug Facility under GDUFA
3. Absorption Systems Partners with Synerzys to Promote Biopharmaceutics Classification System (BCS) Testing of Drugs
4. Absorption Pharmaceuticals to Receive Patent for Premature Ejaculation Topical Medication
5. Vatsala Naageshwaran of Absorption Systems to Present at Disso 2013 International Conference in Mumbai, India on May 3rd
6. Lexicon Presents Preclinical Data On LX2761, a New Clinical Candidate for Diabetes Designed to Reduce Glucose Absorption From Gastrointestinal Tract
7. Absorption Systems Scientists Publish Peer-reviewed Paper on a Key Drug Transporter
8. Absorption Pharmaceuticals Expands Sales and Service Team to Answer Physicians Growing Demand for Promescent
9. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
10. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
11. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 Research ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, ... (Oral, Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is ... a CAGR of 6.1% in the forecast period 2016 ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on ... today announced that patient enrollment in its ongoing ... Duchenne) has exceeded 50% of its 24-patient target. ... in the third quarter of 2016, and to ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 /PRNewswire/ ... Diabetes Tomorrow,s Leaders Scholarship is any indication, the future ... today online at www.diabetesscholars.org by the Diabetes ... stand in the way of academic and community service ... scholarship program since 2012, and continues to advocate for ...
Breaking Medicine Technology:
(Date:6/24/2016)... , ... June 24, 2016 , ... ... and Scientific Sessions in Dallas that it will receive two significant new grants ... grants came as PHA marked its 25th anniversary by recognizing patients, medical professionals ...
(Date:6/24/2016)... ... 2016 , ... Comfort Keepers® of San Diego, CA is excited to announce ... program to drive cancer patients to and from their cancer treatments. Comfort Keepers ... of life and ongoing independence. Getting to and from medical treatments is one ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine ... Making in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards honor ... Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With this ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital ... area economy by obtaining investment capital for emerging technology companies. SCP has ... have already resulted in more than a million dollars of capital investment for ...
(Date:6/24/2016)... MD (PRWEB) , ... June 24, 2016 , ... ... protocols for human induced pluripotent stem (iPS) cells and other difficult to transfect ... G9™ Cloning Medium. The PluriQ™ G9™ Gene Editing System is a ...
Breaking Medicine News(10 mins):